초록 ▼

A preferred method and dosages for the short and long-term treatment of human retroviral infections, or retroviral-like infections, including acquired immunodeficiency syndrome (AIDS) and other manifestations of human immunodeficiency virus (HIV) infection, with 2′,3′-dideoxyinosine (ddl) are disclo

A preferred method and dosages for the short and long-term treatment of human retroviral infections, or retroviral-like infections, including acquired immunodeficiency syndrome (AIDS) and other manifestations of human immunodeficiency virus (HIV) infection, with 2′,3′-dideoxyinosine (ddl) are disclosed, along with a protocol for halting and restarting 2′,3′-dideoxyinosine to minimize certain side effects.

대표청구항 ▼

A method of treating HIV infection which comprises administering to an HIV infected patient in need thereof about 0.4 to 25.6 mg/kg/day of 2′,3′-dideoxyinosine in combination with a member selected from the group consisting of 3′-azido-2′,3′-dideoxythymidine, acyclovir, gancyclovir, pentamidine and

A method of treating HIV infection which comprises administering to an HIV infected patient in need thereof about 0.4 to 25.6 mg/kg/day of 2′,3′-dideoxyinosine in combination with a member selected from the group consisting of 3′-azido-2′,3′-dideoxythymidine, acyclovir, gancyclovir, pentamidine and ribovirin. A method of administering 2′,3′-dideoxyinosine (ddI) to a patient infected with HIV in a manner to minimize treatment induced pancreatitis or other pancreatic dysfunction which comprises: (a) administering said ddI to said patient at a dosage of about 0.4 to about 25.6 mg/kg/day; (b) monitoring said patient for indications of an increased risk of pancreatitis or other pancreatic dysfunction; (c) interrupting the administration of said ddI when said indications are noted; and (d) resuming administration of said ddI at a dosage of about 0.4 to about 14 mg/kg/day when said indications subside. A method of administering 2′,3′-dideoxyinosine (ddI) to a patient infected with HIV in a manner to minimize treatment induced neuropathy which comprises: (a) administering said ddI to said patient at a dosage of about 0.4 to about 25.6 mg/kg/day; (b) monitoring said patient for indications of potential onset of neuropathy; (c) interrupting the administration of said ddI when said indications are noted; and (d) resuming administration of said ddI when said indications subside. A method of administering 2′,3′-dideoxyinosine (ddI) to a patient infected with HIV in a manner to minimize treatment induced hepatitis which comprises: (a) administering said ddI to said patient at a dosage of about 0.4 to about 25.6 mg/kg/day; (b) monitoring said patient for indications of potential onset of hepatitis; (c) interrupting the administration of said ddI when said indications are noted; and (d) resuming administration of said ddI when said indications subside.